Trialbee adds ex-Lundbeck CEO, Bristol-Myers exec to board

Trialbee has added a pair of biopharma heavyweights to its board of directors. Ex-Lundbeck CEO Ulf Wiinberg has taken on the chairman role at the clinical trial software startup, and is joined on the board by Bristol-Myers Squibb’s ($BMY) former SVP of medical R&D, Lars Birgerson.

The addition of board members from the upper echelons of biopharma marks a statement of intent from Trialbee, a Swedish firm that began life 6 years ago with a focus on online patient enrollment. Trialbee has since broadened its ambitions, adding EDC and retention tools to its suite while pulling in more than $8 million in fundraising to expand and globalize its operation. Adding Birgerson and Wiinberg to the board is a continuation of this strategy.

“With my background I clearly see the value Trialbee bring,” Wiinberg said in a statement. “I decided to join the board to be part of the journey from startup to global brand.”

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

Birgerson was more explicit about how he can help Trialbee, explaining that he plans to tap into his “international network” to support the company. Trialbee became more explicit about its own global ambitions when it raised $5 million in a Series A round last year. Some of that cash was earmarked for Trialbee’s attempt to break into the U.S. market.

To date, the eClinical player’s most high-profile successes have come on its home continent. In 2014, Trialbee revealed AstraZeneca ($AZN) and Novo Nordisk ($NVO) had signed up to use its online patient recruitment tools. AstraZeneca secured the rights to use the tools globally, but, given the Big Pharma’s presence in Sweden, it still represented something of a local victory for Trialbee. The Novo Nordisk deal covered the use of the tools in Sweden, Norway and Denmark.

While Birgerson and Wiinberg spent periods of their lives in Scandinavia, their careers took them into the markets Trialbee is targeting and into contact with the decision-makers it wants to meet. Birgerson closed out his career in biopharma with three-year stints at Genentech in San Francisco and Bristol-Myers in New Jersey. And Wiinberg held senior positions at Wyeth in the U.S. and U.K. before returning to Scandinavia to take the reins at Lundbeck.

Related Articles:
Novo Nordisk taps Trialbee for online recruitment of trial patients
AstraZeneca taps Trialbee for online patient recruitment

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.